Michael P Hudson

Dr. Michael P Hudson

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2004 in American Heart Journal
Verified
Journal Article
Closed access
MHMichael P Hudson
Michael P Hudson
COChristopher M O'COnnor
Christopher M O'COnnor
WGWendy A Gattis
Wendy A Gattis
GTGudaye Tasissa
Gudaye Tasissa
VHVic Hasselblad
Vic Hasselblad
EOE.MAgnus Ohman
E.MAgnus Ohman

11 September 2001 in Circulation
Verified
Journal Article
Closed access
PDF file
MHMichael P Hudson
Michael P Hudson
CGChristopher B. Granger
Christopher B. Granger
ETEric J. Topol
Eric J. Topol
KPKaren S. Pieper
Karen S. Pieper
PAPaul W. Armstrong
Paul W. Armstrong
EOE. Magnus Ohman
E. Magnus Ohman
Background Trials report a 2% to 6% incidence of reinfarction after fibrinolysis for acute myocardial infarction (MI). We combined the Global Utilization of Streptokinase and Tissue plasminogen activator (alteplase) for Occluded coronary arteries (GUSTO I) and Global Use of Strategies To Open occluded coronary arteries (GUSTO III) populations to better define frequency, timing, and clinical predictors of in-hospital reinfarction. Methods and Results In 55 911 patients with ST-segment elevation myocardial infarction (MI) who were receiving fibrinolysis, we compared baseline characteristics and mortality rate by reinfarction incidence and developed multivariable logistic regression models to predict in-hospital reinfarction and composite of death or reinfarction. Reinfarction occurred in 2258 patients (4.3%) a median of 3.8 days after fibrinolysis; rates did not differ between GUSTO I (4.0%) and GUSTO III (4.2%) or by fibrinolytic assignment (streptokinase, 4.1%; alteplase, 4.3%; reteplase, 4.5%; combined streptokinase and alteplase, 4.4%; P =0.55). Advanced age, shorter time to fibrinolysis, non-US enrollment, nonsmoking status, prior MI or angina, female sex, anterior MI, and lower systolic blood pressure were associated significantly with reinfarction. Patients with reinfarction had higher mortality at 30 days (11.3% versus 3.5% without reinfarction; odds ratio, 3.5; P <0.001) and from 30 days to 1 year (4.7% versus 3.2%; hazard ratio, 1.5; P <0.001). Significant multivariate predictors of in-hospital death or reinfarction included age, Killip class, systolic and diastolic blood pressures, heart rate, anterior MI, smoking status, prior MI, sex, and country of enrollment (all P <0.001). Conclusion Reinfarction occurs infrequently after fibrinolysis but confers increased risk of 30-day and 1-year mortality. Some predictors of reinfarction differ from known predictors of death after MI. Improved treatment and prevention strategies for reinfarction deserve study.

3 June 2008 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
ASAjay Srivastava
Ajay Srivastava
MHMichael P Hudson
Michael P Hudson
IHIhab Hamoud
Ihab Hamoud
JCJoao Cavalcante
Joao Cavalcante
CPChetan Pai
Chetan Pai
SKScott Kaatz
Scott Kaatz
Introduction: Atrial fibrillation affects an estimated 2.5 million Americans and incurs an average annual stroke risk of 4.5% per year. Despite warfarin reducing stroke risk by approximately 66%, prior studies show warfarin usage rates to be about 50%. However, the methods that define warfarin as "inappropriate underutilization" might not be sensitive enough to pick up relative contraindications. We assessed the inappropriate underutilization of warfarin in atrial fibrillation patients at our hospital by abstracting individual patient charts. Methods: Medical records were reviewed to determine stroke risk factors, warfarin use, and documented contraindications to warfarin use in 364 consecutive patients with atrial fibrillation. Results: Amongst 364 atrial fibrillation patients, 54.6% received warfarin anticoagulation. Overall, 29.5 % of patients had documented reasons for not prescribing warfarin. Primary reasons listed by treating physicians included: gastrointestinal bleed 10.7%, secondary/transient atrial fibrillation 8.2%, and fall risk 6.3%. Only 7.1% of the patients had no documented reasons for the lack of warfarin use. Conclusion: Consistent with previous reports, 45.4% of patients in this atrial fibrillation cohort were not prescribed warfarin. However, after reviewing medical charts for documented reasons why warfarin was not used, the inappropriate underutilization rate was only 7.1%. These findings suggest that studies utilizing administrative database and ICD-9 CM coding might overestimate warfarin underutilization.

1 March 2011 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Open access
PDF file
MHMichael P Hudson
Michael P Hudson
PAPaul W. Armstrong
Paul W. Armstrong
WOWilliam W. O'NEil
William W. O'NEil
ASAmanda L. Stebbins
Amanda L. Stebbins
WWW. Douglas Weaver
W. Douglas Weaver
CGChristopher B. Granger
Christopher B. Granger
Background—: Prior studies demonstrate a direct relationship between treatment delays to primary percutaneous intervention and mortality in patients with ST-segment elevation myocardial infarction (STEMI). This analysis compared the relationship of symptom onset-to-balloon time and door-to-balloon time on mortality in patients with STEMI. Methods and Results—: We analyzed different treatment delays (symptom onset-to-balloon time, door-to-balloon time) and mortality in 5745 STEMI patients. Baseline characteristics, flow grade, 90-day mortality, and clinical outcomes were compared in patients stratified by treatment delay. Multivariable logistic regression modeling was performed to assess the independent and relative effect of each treatment delay on 90-day mortality. Female sex, increased age, and worse thrombolysis in myocardial infarction flow grade were significantly associated with longer symptom onset-to-balloon times and door-to-balloon times. Longer symptom onset-to-balloon time was significantly associated with worse 90-day mortality (3.7%, 4.2%, and 6.5% for time delays 5 hours, respectively, P <0.0001). Similarly, longer door-to-balloon times were significantly associated with worse 90-day mortality (3.2%, 4.0%, 4.6%, and 5.3% for delays <60 minutes, 60 to 90 minutes, 90 to 120 minutes, and ≥120 minutes respectively, P <0.0001). In a multivariate model of 90-day mortality, door-to-balloon time (χ 2 6.0, P <0.014), and symptom onset-to-hospital arrival (χ 2 9.8, P <0.007) remained independent determinants. Conclusions—: Both symptom onset-to-balloon time and hospital door-to-balloon time are strongly associated with 90-day mortality following STEMI. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00091637.

31 March 2010 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
MHMichael P Hudson
Michael P Hudson
AGAdam Greenbaum
Adam Greenbaum
LBLaura Brenton
Laura Brenton
CGC. Michael Gibson
C. Michael Gibson
RSRobert Siegel
Robert Siegel
WWW. Douglas Weaver
W. Douglas Weaver

1 October 2018 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
RNRichard M. Nowak
Richard M. Nowak
GJGordon Jacobsen
Gordon Jacobsen
RCRobert H. Christenson
Robert H. Christenson
MMMichele Moyer
Michele Moyer
MHMichael P Hudson
Michael P Hudson
JMJames McCord
James McCord